

Gerald Willimsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7034212/publications.pdf>

Version: 2024-02-01

47
papers

3,613
citations

279701

23
h-index

223716

46
g-index

48
all docs

48
docs citations

48
times ranked

7952
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	1.6	766
2	Guidelines for the use of flow cytometry and cell sorting in immunological studies [*] . <i>European Journal of Immunology</i> , 2017, 47, 1584-1797.	1.6	505
3	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. <i>Nature</i> , 2015, 521, 94-98.	13.7	451
4	Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. <i>Nature</i> , 2005, 437, 141-146.	13.7	385
5	Characterization of cspB, a <i>Bacillus subtilis</i> inducible cold shock gene affecting cell viability at low temperatures. <i>Journal of Bacteriology</i> , 1992, 174, 6326-6335.	1.0	234
6	Structure in solution of the major cold-shock protein from <i>Bacillus subtilis</i> . <i>Nature</i> , 1993, 364, 169-171.	13.7	222
7	Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. <i>Journal of Experimental Medicine</i> , 2008, 205, 1687-1700.	4.2	105
8	Commensal microflora and interferon- β promote steady-state interleukin-7 production <i>in vivo</i> . <i>European Journal of Immunology</i> , 2010, 40, 2391-2400.	1.6	77
9	Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. <i>Cancer Immunology Research</i> , 2017, 5, 137-147.	1.6	73
10	RNA Levels of Human Retrovirus Receptors Pit1 and Pit2 Do Not Correlate with Infectibility by Three Retroviral Vector Pseudotypes. <i>Human Gene Therapy</i> , 1998, 9, 2619-2627.	1.4	63
11	The adaptive immune response to sporadic cancer. <i>Immunological Reviews</i> , 2007, 220, 102-112.	2.8	54
12	Overproduction, crystallization, and preliminary X-ray diffraction studies of the major cold shock protein from <i>Bacillus subtilis</i> , CspB. <i>Proteins: Structure, Function and Bioinformatics</i> , 1992, 14, 120-124.	1.5	45
13	The Sorting Receptor Sortilin Exhibits a Dual Function in Exocytic Trafficking of Interferon- β and Granzyme A in T Cells. <i>Immunity</i> , 2012, 37, 854-866.	6.6	45
14	Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. <i>Gene Therapy</i> , 2000, 7, 2007-2014.	2.3	43
15	Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. <i>Journal of Clinical Investigation</i> , 2013, 123, 1032-1043.	3.9	42
16	CD96 expression determines the inflammatory potential of IL-9-producing Th9 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2940-E2949.	3.3	36
17	Oleate but not stearate induces the regulatory phenotype of myeloid suppressor cells. <i>Scientific Reports</i> , 2017, 7, 7498.	1.6	35
18	Fas expression by tumor stroma is required for cancer eradication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2276-2281.	3.3	34

#	ARTICLE	IF	CITATIONS
19	Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. <i>Cancer Research</i> , 2017, 77, 3577-3590.	0.4	32
20	Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. <i>World Journal of Urology</i> , 2005, 23, 166-174.	1.2	30
21	Tumor-induced antibodies resemble the response to tissue damage. <i>International Journal of Cancer</i> , 2005, 115, 456-462.	2.3	27
22	Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. <i>Blood</i> , 2013, 121, 1740-1748.	0.6	25
23	Mapping of the <i>Bacillus subtilis</i> cspB gene and cloning of its homologs in thermophilic, mesophilic and psychrotrophic bacilli. <i>Gene</i> , 1993, 136, 277-280.	1.0	24
24	The immune response to sporadic colorectal cancer in a novel mouse model. <i>Oncogene</i> , 2010, 29, 6591-6602.	2.6	23
25	Influence of CD80, Interleukin-2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expansion, Function, and Survival of Tumor-Specific CTLs. <i>Clinical Cancer Research</i> , 2005, 11, 1733-1742.	3.2	22
26	Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. <i>Nature Communications</i> , 2017, 8, 14447.	5.8	22
27	Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients with Metastatic Renal Cell Carcinoma. <i>Human Gene Therapy</i> , 2010, 21, 285-297.	1.4	19
28	Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. <i>Gene Therapy</i> , 2011, 18, 354-363.	2.3	18
29	Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. <i>Clinical Cancer Research</i> , 2018, 24, 3644-3655.	3.2	18
30	High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination. <i>Molecular Medicine</i> , 2012, 18, 1499-1508.	1.9	16
31	Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation. <i>Frontiers in Immunology</i> , 2019, 10, 1776.	2.2	15
32	In Vivo Imaging of an Inducible Oncogenic Tumor Antigen Visualizes Tumor Progression and Predicts CTL Tolerance. <i>Journal of Immunology</i> , 2010, 184, 2930-2938.	0.4	12
33	Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 513-523.	2.0	11
34	ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice. <i>Cancer Research</i> , 2018, 78, 3243-3254.	0.4	11
35	Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies. <i>Leukemia</i> , 2019, 33, 1039-1043.	3.3	11
36	T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 378-389.	3.2	11

#	ARTICLE	IF	CITATIONS
37	In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo. <i>ELife</i> , 2021, 10, .	2.8	10
38	Lymphocyte access to lymphoma is impaired by high endothelial venule regression. <i>Cell Reports</i> , 2021, 37, 109878.	2.9	9
39	Cooperation of genes in HPV16 <i>E6/E7</i> -dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. <i>Carcinogenesis</i> , 2020, 41, 1605-1615.	1.3	8
40	Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes. <i>Gene Therapy</i> , 2002, 9, 1438-1446.	2.3	7
41	Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key?. <i>Oncotarget</i> , 2013, 4, 1117-1118.	0.8	6
42	SV40 large T antigen-transformed human primary normal and cancerous mammary epithelial cells are phenotypically similar but can be distinguished in 3D culture with selection medium. <i>International Journal of Cancer</i> , 2008, 123, 1516-1525.	2.3	4
43	Identification and ranking of recurrent neo-epitopes in cancer. <i>BMC Medical Genomics</i> , 2019, 12, 171.	0.7	2
44	Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires. <i>Cancers</i> , 2022, 14, 1842.	1.7	2
45	EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice. <i>JCI Insight</i> , 2022, , .	2.3	2
46	Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice. <i>Blood</i> , 2018, 132, 924-934.	0.6	1
47	TCR in Renal Cell Carcinoma: Models, Monitoring and Therapy. <i>Journal of Immunotherapy</i> , 2005, 28, 618.	1.2	0